Truist Securities Maintains Buy on Genmab, Raises Price Target to $45

Benzinga · 2d ago
Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $45.